SE426834B - SET TO MAKE 15ALFA, 16ALFA METHYLENE-4-OSTREN-17BETA OILS - Google Patents
SET TO MAKE 15ALFA, 16ALFA METHYLENE-4-OSTREN-17BETA OILSInfo
- Publication number
- SE426834B SE426834B SE7713896A SE7713896A SE426834B SE 426834 B SE426834 B SE 426834B SE 7713896 A SE7713896 A SE 7713896A SE 7713896 A SE7713896 A SE 7713896A SE 426834 B SE426834 B SE 426834B
- Authority
- SE
- Sweden
- Prior art keywords
- methylene
- ethinyl
- methyl
- estren
- hydroxy
- Prior art date
Links
- 239000003921 oil Substances 0.000 title description 6
- 238000000034 method Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 150000007522 mineralic acids Chemical group 0.000 claims description 4
- 150000002902 organometallic compounds Chemical class 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 125000000468 ketone group Chemical group 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 29
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000004587 chromatography analysis Methods 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- -1 steroid alcohols Chemical class 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 7
- 229910052744 lithium Inorganic materials 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 150000008064 anhydrides Chemical class 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 235000006408 oxalic acid Nutrition 0.000 description 4
- 230000000757 progestagenic effect Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- AVGAIPMGSIOHFZ-UHFFFAOYSA-N dichloromethane;2-propan-2-yloxypropane Chemical compound ClCCl.CC(C)OC(C)C AVGAIPMGSIOHFZ-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- LROBJRRFCPYLIT-UHFFFAOYSA-M magnesium;ethyne;bromide Chemical compound [Mg+2].[Br-].[C-]#C LROBJRRFCPYLIT-UHFFFAOYSA-M 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- NKRNGKIEDAVMHL-UHFFFAOYSA-L dihydroxy(dioxo)chromium;pyridine Chemical compound O[Cr](O)(=O)=O.C1=CC=NC=C1 NKRNGKIEDAVMHL-UHFFFAOYSA-L 0.000 description 2
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229960004719 nandrolone Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 2
- CPUKWYXYHPOQJH-RDQPJNLGSA-N (8r,9s,10s,13s,14s)-17-ethenyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C(=CC4)C=C)[C@@H]4[C@@H]3CCC21 CPUKWYXYHPOQJH-RDQPJNLGSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- QNVAUOOHLRHGAV-UHFFFAOYSA-N C(C)(C)(C)O[AlH2].[Li] Chemical compound C(C)(C)(C)O[AlH2].[Li] QNVAUOOHLRHGAV-UHFFFAOYSA-N 0.000 description 1
- RWDQBDMJLBGAJN-UHFFFAOYSA-M C(CC)(=O)[Mg]Br Chemical compound C(CC)(=O)[Mg]Br RWDQBDMJLBGAJN-UHFFFAOYSA-M 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- VIWZVFVJPXTXPA-UHFFFAOYSA-N N-(2-Carboxymethyl)-morpholine Chemical compound OC(=O)CN1CCOCC1 VIWZVFVJPXTXPA-UHFFFAOYSA-N 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CIHXIRAAMAUYLZ-UHFFFAOYSA-N [K+].[K+].[C-]#[C-] Chemical compound [K+].[K+].[C-]#[C-] CIHXIRAAMAUYLZ-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000001337 aliphatic alkines Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000004791 alkyl magnesium halides Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- DAPZDAPTZFJZTO-UHFFFAOYSA-N heptanoyl heptanoate Chemical compound CCCCCCC(=O)OC(=O)CCCCCC DAPZDAPTZFJZTO-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000001145 hydrido group Chemical group *[H] 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- OUIQXDUPDANAAW-UHFFFAOYSA-N lithium;chloroethyne Chemical compound [Li+].ClC#[C-] OUIQXDUPDANAAW-UHFFFAOYSA-N 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- DQEUYIQDSMINEY-UHFFFAOYSA-M magnesium;prop-1-ene;bromide Chemical compound [Mg+2].[Br-].[CH2-]C=C DQEUYIQDSMINEY-UHFFFAOYSA-M 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- RAFYDKXYXRZODZ-UHFFFAOYSA-N octanoyl octanoate Chemical compound CCCCCCCC(=O)OC(=O)CCCCCCC RAFYDKXYXRZODZ-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- KFUSEUYYWQURPO-OWOJBTEDSA-N trans-1,2-dichloroethene Chemical group Cl\C=C\Cl KFUSEUYYWQURPO-OWOJBTEDSA-N 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
7713896-4 2 Såsom acylgrupper R2 och R4 kommer fysiologiskt fördragbara syra- rester ifråga, som härrör från syror som vanligtvis används för för- estring av steroidalkoholer. Härtill räknas bl.a. organiska karbon- syror med 1-18 kolatomer, som tillhör den alifatiska, alicykliska, aromatiska eller heterocykliska serien och som kan vara mättade el- ler omättade, en- eller flerbasiska och/eller substituerade, varvid som exempel på substituenter skall nämnas alkyl-, hydroxi-, oxo- el- ler aminogrupper eller halogenatomer. Härtill räknas även de brukli- ga oorganiska syrorna. 7713896-4 2 As acyl groups R2 and R4, there are physiologically acceptable acid residues which originate from acids which are usually used for the esterification of steroid alcohols. This includes e.g. Organic carboxylic acids having 1 to 18 carbon atoms, belonging to the aliphatic, alicyclic, aromatic or heterocyclic series, which may be saturated or unsaturated, mono- or polybasic and / or substituted, examples of which are alkyl, hydroxy, oxo or amino groups or halogen atoms. This also includes the usual inorganic acids.
Såsom syror kommer lägre, mellanliggande och högre karbonsyror, fö- reträdesvis sâdana med upp till 15 kolatomer, ifråga, av vilka exem- pelvis skall nämnas myr-, ättik-, propion-, smör-, isosmör-, vale- rian-, isovalerian-, kapron-, önant-, kapryl-, pelargon-, kaprin-, undecyl-, laurin-, tridecyl-, myristin-, pentadecyl-, trimetylättik-, dietylättik-, tert.-butylättik-, cyklopentylättik-, cyklohexylättik-, monoklorättik-, diklorättik- och triklorättik-, aminoättik-, dietyl- aminoättik-, piperidinoättik-, morfolinoättik-,'mjölk, bärnstens-, adipin-, bensoe-, nikotin- och isonikotinsyra och furan-2-karbonsyra..As acids, there are lower, intermediate and higher carboxylic acids, preferably those having up to 15 carbon atoms, in question, of which, for example, ant, acetic, propionic, butyric, isobutyric, valerian, isovaleric are mentioned. -, kapron, önant-, capryl-, geranium-, kaprin-, undecyl-, laurin-, tridecyl-, myristin-, pentadecyl-, trimethyl-vinegar-, diethyl-vinegar-, tert-butyl-acetic- monochloroacetic, dichloroacetic and trichloroacetic, aminoacetic, diethylaminoacetic, piperidinoacetic, morpholinoacetic acid, lactic, succinic, adipic, benzoic, nicotinic and isonicotinic acids and furan-2-carboxylic acid.
Dessutom kommer de brukliga oorganiska syrorna, t.ex. svavel- och fosforsyra, ifråga.In addition, the usual inorganic acids, e.g. sulfuric and phosphoric acid, in question.
För att framställa vattenlösliga preparat kommer_vanligtvis de bruk- liga estrarna ifråga. Såsom exempel skall nämnas estrar av bärnstens- syra, adipinsyra, svavelsyra och fosforsyra, som eventuellt överföres till alkalimetallsalter.In order to prepare water-soluble preparations, the usual esters are usually used. Examples which may be mentioned are esters of succinic acid, adipic acid, sulfuric acid and phosphoric acid, which are optionally converted into alkali metal salts.
Då föreningarna framställda medelst sättet enligt uppfinningen upp- visar värdefulla steroidhormonegenskaper, kan de insättas såsom far- maceutika.When the compounds prepared by the method of the invention exhibit valuable steroid hormone properties, they can be used as pharmaceuticals.
Sålunda utmärker sig steroider med formeln I genom en stark gestagen verkan. 18-metyl-17a-etinyl-15u,16u-metylen-19-nortestosteron (C) visar sig exempelvis i befruktningshämningstest samt i det brukliga Claubcrgtestet överlägsen den kända föreningen 18-mety1-17u-etinyl- -19-nortestosteron (D). I nedanstående tabell anges resultaten vid subkutan administrering av (C) och (D) på kaniner i befruktningshäm- ningstestet och i Clauberg-testet. 7713896-4, 3 Tabell B f kt ' - hšmninggtggï Clauberg_test Förening ' Dos (mg) Verkan Dos (mg) Me Phail C 18-metyl-17d-etinyl- -15d,16a-metylen- -19-nortestosteron 0,3 aktiv 0,01 2,2 D 18-metyl-17d-etinyl- -19-nortestosteron 0,5 inaktiv 0,01 1,0 Av tabellen framgår entydigt den högre aktiviteten, dvs den överlägs- na verkan av föreningarna enligt uppfinningen.Thus, steroids of formula I are distinguished by a strong progestogenic action. 18-methyl-17α-ethinyl-15u, 16u-methylene-19-nortestosterone (C) is found, for example, in fertility inhibition tests and in the usual Clauburg test superior to the known compound 18-methyl-17u-ethinyl-19-nortestosterone (D). The table below lists the results of subcutaneous administration of (C) and (D) to rabbits in the fertility inhibition test and in the Clauberg test. 7713896-4, 3 Table B f kt '- inhibition test Clauberg_test Compound' Dose (mg) Effect Dose (mg) Me Phail C 18-methyl-17d-ethinyl- -15d, 16a-methylene--19-nortestosterone 0.3 active 0.01 2.2 D 18-methyl-17d-ethinyl--19-nortestosterone 0.5 inactive 0.01 1.0 The table clearly shows the higher activity, ie the superior effect of the compounds according to the invention.
De högre estrarna av föreningarna enligt uppfinningen utmärker sig dessutom genom en protraherad verkan.The higher esters of the compounds of the invention are further characterized by a contracted action.
De gestagena föreningarna enligt uppfinningen kan exempelvis användas i antikonceptionspreparat, varvid de såsom gestagenkomponent insättes i kombination med en östrogenverksam hormonkomponent, t.ex. etinyl- östradiol, eller såsom ensam verksam komponent. De gestagena förenin- garna kan exempelvis även införas i preparat för behandling av gyne- kologiska störningar.The progestogenic compounds according to the invention can be used, for example, in contraceptive preparations, in which case they are used as a progestogen component in combination with an estrogen-active hormone component, e.g. ethinyl estradiol, or as the sole active component. The progestogenic compounds can, for example, also be introduced into preparations for the treatment of gynecological disorders.
De nya föreningarna beredes för användning med de inom den galeniska farmacin brukliga tillsatserna, bârarna och smakkorrigerande ännena på i och för sig kända sätt till de brukliga läkemedelformerna. För oral administrering kommer isynnerhet tabletter, dragéer, kapslar, piller, suspensioner och lösningar ifråga och för parenteral administ- rering kommer isynnerhet oljelösningar, exempelvis sesamolja- eller ricinoljalösningar, ifråga, som eventuellt dessutom kan innehålla ett utspädningsmedel, t.ex. bensylbensoat eller bensylalkohol. Kon- centrationen av den verksamma substansen i de sålunda formulerade läkemedlen beror på administreringsformen.The new compounds are prepared for use with the additives, carriers and taste-correcting agents customary in galenic pharmacy in a manner known per se for the usual pharmaceutical forms. For oral administration, tablets, dragees, capsules, pills, suspensions and solutions are particularly relevant, and for parenteral administration, oil solutions, for example sesame oil or castor oil solutions, are particularly relevant, which may additionally contain a diluent, e.g. benzyl benzoate or benzyl alcohol. The concentration of the active substance in the drugs thus formulated depends on the form of administration.
Föreningarna framställda enligt uppfinningen kan även utgöra mellan- produkter för sådana farmakologiskt värdefulla steroider, som er- hålles genom i och för sig kända omvandlingsförfaranden, t.ex. om- lagring, hydrering, dehydrering etc.The compounds prepared according to the invention can also constitute intermediates for such pharmacologically valuable steroids, which are obtained by conversion methods known per se, e.g. re-storage, hydration, dehydration, etc.
Sättet enligt uppfinningen för framställning av 15u,16u-metylen-4- -östren-176-oler med den allmänna formeln I 7713896-4 X i vilken R1, R2, Rï X och R4 betecknar detsamma som ovan, känneteck- nas av att man på i och för sig känt sätt omsätter en 15u,16u-mety- len-17-oxo-5(6)- eller 5(10)-östren med den allmänna formeln II > II // Y där R1 betecknar detsamma som ovan och Y betecknar en företrädesvis som ketal skyddad ketogrupp, med en metallorganisk förening som av- ger resten R3, avspaltar en primärt införd skyddsgrupp och, allt ef- ter den slutligen önskade betydelsen av X, R2, R3 och R , eventuellt därefter på i och för sig känt sätt förestrar 17-hydroxigruppen.OCh/ eller reducerar 3-ketogruppen och förestrar i molekylen förekommande fria hydroxigrupper.The process according to the invention for the preparation of 15u, 16u-methylene-4-oestren-176-ols of the general formula I in which R1, R2, R1, X and R4 denote the same as above, is characterized in that in a manner known per se, a 15u, 16u-methylene-17-oxo-5 (6) - or 5 (10) -esters of the general formula II> II // Y react where R1 represents the same as above and Y represents a keto-group preferably protected as ketal, with an organometallic compound which gives off the residue R3, cleaves a primarily introduced protecting group and, depending on the finally desired meaning of X, R2, R3 and R, optionally thereafter on and for esterifies the 17-hydroxy group.OCh / or reduces the 3-keto group and esterifies free hydroxy groups present in the molecule.
Omsättningen med en metallorganisk förening kan utföras medelst kän- da sätt, varvid den organiska resten är R3 och varvid det kan röra sig om en alkylmagnesiumhalogenid, t.ex. metylmagnesiumbromid eller -jodid, en alkenylmagnesium- och/eller alkenylzinkhalogenid, t.ex. vinylmagnesiumbromid eller allylmagnesiumbromid, en alkinylmagnesi- umhalogenid, t.ex. etinylmagnesiumbromid, propionylmagnesiumbromid eller propinylzinkbromid, eller en alkalimetallacetylid, t.ex. ka- liumacetylid.The reaction with an organometallic compound can be carried out by known methods, the organic residue being R 3 and in which case it may be an alkylmagnesium halide, e.g. methylmagnesium bromide or iodide, an alkenylmagnesium and / or alkenylzinc halide, e.g. vinylmagnesium bromide or allylmagnesium bromide, an alkinylmagnesium halide, e.g. ethinylmagnesium bromide, propionylmagnesium bromide or propinylzinc bromide, or an alkali metal acetylide, e.g. potassium acetylide.
Den använda metallorganiska föreningen kan även bildas in situ och bringas att reagera med 17-ketonen med formeln II. Sålunda låter man. exempelvis för omsättning med metallorganiska alkinylföreningar en alkin, kloralkin eller alkadiin och en alkalimetall inverka på keto- nen i ett lämpligt lösningsmedel, företrädesvis i närvaro av en ter- 7713896-4 tiär alkohol eller av ammoniak eventuellt vid förhöjt tryck.The organometallic compound used can also be formed in situ and reacted with the 17-ketone of formula II. Thus one sounds. for example, for reaction with organometallic alkinyl compounds an alkine, chloroalkine or alkadiene and an alkali metal act on the ketone in a suitable solvent, preferably in the presence of a tertiary alcohol or of ammonia possibly at elevated pressure.
Reduktionen av 17-ketogruppen utföres i en föredragen utföringsform vid förekomst av en, t.ex. som ketal, skyddad 3-ketogrupp. Ketal- resterna härrör från alkoholer, t.ex. etylenglykol och 2,2-dimetyl- -1,3-propandiol, som på brukligt sätt användes för att skydda fria oxogrupper.The reduction of the 17-keto group is carried out in a preferred embodiment in the presence of a, e.g. as ketal, protected 3-keto group. The ketal residues are derived from alcohols, e.g. ethylene glycol and 2,2-dimethyl--1,3-propanediol, which are commonly used to protect free oxo groups.
Reduktionen av 3~ketogruppen kan utföras på för fackmannen kända sätt. Den kan exempelvis ske genom hydrering i närvaro av en bruklig katalysator, som i närvaro av väte åstadkommer reduktion av omättade sexringketoner. Reduktionen kan dock även utföras med metallhydrider eller hydridokomplexföreningar. Såsom exempel skall nämnas natrium- borhydrid, litiumaluminiumhydrid, natriumtrimetoxiborhydrid och li- tium-tert.-butoxialuminiumhydrid.The reduction of the 3-keto group can be carried out in ways known to those skilled in the art. It can be effected, for example, by hydrogenation in the presence of a conventional catalyst which, in the presence of hydrogen, results in the reduction of unsaturated sex ring ketones. However, the reduction can also be carried out with metal hydrides or hydrido complex compounds. Examples which may be mentioned are sodium borohydride, lithium aluminum hydride, sodium trimethoxyborohydride and lithium tert-butoxyaluminum hydride.
För den anslutande förestringen kommer de förfaringssätt, som brukar användas inom steroidkemin för förestring av steroidalkoholer, ifråga.For the subsequent esterification, the procedures commonly used in steroid chemistry for the esterification of steroid alcohols come into play.
För acylering av en hydroxigrupp i 3-ställning skall exempelvis näm- nas omsättning med en syraanhydríd i närvaro av en tertiär amin vid rumstemperatur. För förestring av en 178-hydroxigrupp skall exempel- vis nämnas omsättning med syraanhydrider i närvaro av starka syror, t.ex. p-toluensulfonsyra, eller omsättning med en syraanhydrid i när- varo av en tertiär amin i värme. De sistnämnda förfaringssätten kan även användas för att omvandla 3,17-dihydroxisteroider till diacylat.For acylation of a hydroxy group in the 3-position, mention should be made, for example, of reaction with an acid anhydride in the presence of a tertiary amine at room temperature. For esterification of a 178-hydroxy group, for example, reaction with acid anhydrides in the presence of strong acids, e.g. p-toluenesulfonic acid, or reaction with an acid anhydride in the presence of a tertiary amine in heat. The latter procedures can also be used to convert 3,17-dihydroxisteroids to diacylate.
Avspaltningen av ketoskyddsgruppen utföres på för fackmannen kända sätt. Eör deketalisering kommer exempelvis mineralsyror, t.ex. per- klorsyra, svavelsyra eller klorvätesyra, eller organiska syror, t.ex. oxalsyra, ifråga.The cleavage of the keto protecting group is carried out in a manner known to those skilled in the art. For decetalization, for example, mineral acids, e.g. perchloric acid, sulfuric acid or hydrochloric acid, or organic acids, e.g. oxalic acid, in question.
Framställning av de som utgângsföreningar använda 15u,16a-metylen- -174mw-5(6)- eller 5(10-östrener med formeln II beskrives i form av ketaler medelst nedanstående exempel A och B.Preparation of the 15u, 16a-methylene-174mw-5 (6) - or 5 (10-estrenes of formula II used as starting compounds) is described in the form of ketals by means of Examples A and B below.
A) 3,3-(2',2'-dimetyl-1',3'-propylendioxi)-18-metyl-15d,16d-metylen- -5(6)- eller 5(10)-östren-17-on. 46,2 g naturlig 18-metyl-18-nor-4,16-pregnadien-3,20-dion upphettas i 2,5 l hvnsen med 37,1 g 2,2-dimetyl-1,3-propandiol och 2,7 g p- -Lolutnsulfonsyra 6 timmar med vattenavskiljare och återflöde. Reak- tionslösningen tvättas efter avkylning med en mättad natriumvätekar- 2771ss9s-4- bonatlösning och med vatten, torkas över natriumsulfat och induns- tas i vakuum till torrhet. Den sålunda erhållna återstoden kromato- graferas på silikagel, och man erhåller, efter omkristallisering från diisopropyleter, 28,6 g naturlig_3,3-(2',2'-dimetyl-123'-propylen- dioxi)-18-metyl-19-nor-5,16- resp. 5(10)-16-pregnadien-20-on. Smp: 145-1ss°c. uv: :243 = 8530. ' 38,2 g naturlig 3,3-(2',2'-dimetyl-1',3'-propylendioxi)-18-metyl-19- -nor-5,16- resp. 5(10),16-pregnadien-20-on löst i 229 ml tetrahydro- furan sättes droppvis till en till -20°C kyld lösning av 29,2 g ka- lium-tert.-butylat i 343 ml dimetylformamid, 57 ml abs. tert.-buta- nol och 22,9 ml trimetylfosfit under genomledande av syra inom 30 minuter. Blandningen omröres därefter ytterligare 1 timme vid -ZOOC under genomledande av syra. Reaktionslösningen förs därpå in i med ättiksyra svagt surgjort isvatten. Den utskilda fällningen avfiltre- ras, tvättas väl med vatten, löses i metylenklorid och torkas över _ natriumsulfat. Den efter indunstning erhållna återstoden kromatogra- feras på silikagel och man erhåller, efter omkristallisering från diisopropyleter-metylenklorid, 15,5 g naturlig 17-hydroxi-3,3-(2',2'- -dimetyl-1',3'-propylendioxi)-18-metyl-19-nor-5,15- resp. 5(1Ü,15- -pregnadien-20-on. Smp.: 202-214°C._ 14,0 g naturlig 17-hydroxi-3,3-(2',2'-dimetyl-1',3'-propylendioxi)- -18-metyl-19-nor~5,15- resp. 5(10),15-pregnadien-20-on löses i 140 ml abs. tetrahydrofuran och därtill sättes 14,0 g litiumtri-tert.- butoxialanat och blandningen får stå 1 timme vid rumstemperatur.A) 3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -18-methyl-15d, 16d-methylene--5 (6) - or 5 (10) -estrene-17- on. 46.2 g of natural 18-methyl-18-nor-4,16-pregnadiene-3,20-dione are heated in 2.5 l of the mixture with 37.1 g of 2,2-dimethyl-1,3-propanediol and 2, 7 g p- -Lutulene sulfonic acid 6 hours with water separator and reflux. The reaction solution is washed after cooling with a saturated sodium bicarbonate solution and with water, dried over sodium sulphate and evaporated in vacuo to dryness. The residue thus obtained is chromatographed on silica gel to give, after recrystallization from diisopropyl ether, 28.6 g of natural -3,3- (2 ', 2'-dimethyl-123'-propylenedioxy) -18-methyl-19- nor-5,16- resp. 5 (10) -16-pregnadien-20-one. Mp: 145-1ss ° c. uv:: 243 = 8530. 38.2 g of natural 3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -18-methyl-19--nor-5,16- resp. (10), 16-Pregnadien-20-one dissolved in 229 ml of tetrahydrofuran is added dropwise to a solution cooled to -20 ° C of 29.2 g of potassium tert-butylate in 343 ml of dimethylformamide, 57 ml abs. tert-butanol and 22.9 ml of trimethyl phosphite with conduction of acid within 30 minutes. The mixture is then stirred for a further 1 hour at -ZOOC while passing acid. The reaction solution is then introduced into ice water slightly acidified with acetic acid. The separated precipitate is filtered off, washed well with water, dissolved in methylene chloride and dried over sodium sulphate. The residue obtained after evaporation is chromatographed on silica gel to give, after recrystallization from diisopropyl ether-methylene chloride, 15.5 g of natural 17-hydroxy-3,3- (2 ', 2'-dimethyl-1', 3'- propylenedioxy) -18-methyl-19-nor-5,15- resp. (1U, 15- -pregnadien-20-one. Mp: 202-214 ° C. 14.0 g of natural 17-hydroxy-3,3- (2 ', 2'-dimethyl-1', 3 ' -propylenedioxy) -18-methyl-19-nor-5,15- and 5 (10), 15-pregnadien-20-one are dissolved in 140 ml of absolute tetrahydrofuran and 14.0 g of lithium tri-tert are added thereto. butoxyalanate and the mixture is allowed to stand for 1 hour at room temperature.
Reaktionslösningen förs in i isvatten, surgöres med utspädd svavel- syra och extraheras med metylenklorid. Man kromatograferar den efter torkning och indunstning erhållna râprodukten på silikagel, varvid man erhåller 13,0 g naturlig 17,20-C-dihydroxi-3,3-(2',2'-dimetyl- -1',3'-propylendioxi)-18-metyl-19-nor-5,15- resp. 5(10),15~pregnadi- en upphettas i 185 ml abs. eter och 185 ml abs. etylenglykoldimetyl- eter med 16,8 ml metylenjodid och 20,8 g zinkkoppar 5 timmar med återflöde. Därefter spädes blandningen med metylenklorid, tvättas med en mättad ammoniumkloridlösning och med vatten, torkas över nat- riumsulfat och indunstas i vakuum till torrhet. Återstoden kromato- graferas på silikagel, varvid man erhåller 6,8 g naturlig 17,20ç-di- hydroxi-3,3-(2',2'¿dimetyl-1',3'-propylendioxi)-18-metyl-15a,16a-me- tylen-19-nor-S- resp. 5(10)-pregnen.The reaction solution is introduced into ice water, acidified with dilute sulfuric acid and extracted with methylene chloride. The crude product obtained after drying and evaporation is chromatographed on silica gel to give 13.0 g of natural 17,20-C-dihydroxy-3,3- (2 ', 2'-dimethyl--1', 3'-propylenedioxy). -18-methyl-19-nor-5,15- resp. 5 (10), 15 ~ pregnadi- en is heated in 185 ml abs. ether and 185 ml abs. ethylene glycol dimethyl ether with 16.8 ml of methylene iodide and 20.8 g of zinc copper for 5 hours at reflux. The mixture is then diluted with methylene chloride, washed with saturated ammonium chloride solution and with water, dried over sodium sulfate and evaporated in vacuo to dryness. The residue is chromatographed on silica gel to give 6.8 g of natural 17,20c-dihydroxy-3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -18-methyl-15a , 16a-methylene-19-nor-S- resp. 5 (10) -pregnen.
Till 9,0 g naturlig 17,20;-dihydroxi~3,3~(2',2'-dimetyl-1',3'-pro- 7713896-4 pylendioxi)-18-metyl-15u,16a-metylen-19~nor~5- resp. 5(10)-pregnen i 360 ml metylenklorid sättes 27 g pyridin-kromsyrakomplex (fram- ställt genom omsättning av krom(VI)oxid i pyridin och isolering av det utskilda komplexet) och blandningen omröres 3 timmar vid rums- temperatur. Reaktionslösningen filtreras genom ett porslinsfilter och filtratet indunstas i vakuum. Återstoden kromatograferas på silika- gel, varvid man erhåller 3,9 g naturlig 3,3-(2',2'-dimetyl-1',3'- -propylendioxi)-18-metyl-15a,16a-metylen-5- resp. 5(10)-östren-17-on.To 9.0 g of natural 17,20; -dihydroxy-3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -18-methyl-15u, 16a-methylene- 19 ~ nor ~ 5- resp. The 5 (10) impregnated in 360 ml of methylene chloride is added 27 g of pyridine-chromic acid complex (prepared by reacting chromium (VI) oxide in pyridine and isolating the separated complex) and the mixture is stirred for 3 hours at room temperature. The reaction solution is filtered through a porcelain filter and the filtrate is evaporated in vacuo. The residue is chromatographed on silica gel to give 3.9 g of natural 3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -18-methyl-15a, 16a-methylene-5- resp. 5 (10) -estren-17-one.
B) 3,3~(2',2'-dimetyl-1',3'-propylendioxi)-15a,16a-metylen-5(6)- eller 5(10)-östren-17-on. 5,0 g 19-nor-4,16-pregnadien-3,20-dion upphettas i 250 ml bensen med 4,0 g 2,2-dimetyl-1,3-propandiol och 300 mg p-toluensulfonsyra 2 tim- mar med vattenavskiljare och âterflöde. Man upparbetar blandningen såsom beskrivits i exempel A_ Man erhåller, efter kromatografering på silikagel, 4,9 g 3,3-(2',2'-dim/etyl-1',3'-propylendioxi)-19-nor- -5,16- resp. 5(10),16-pregnadien-20-on. UV: e239 = 9200. 5,0 g 3,3-(2',2'-dimetyl-1',3'-propylendioxi)-19-nor-5,16- resp. 5(10)A6-pregnadien-20-on omsättes med kalium-tert.-butylatlösning, syre och trimetylfosfit vid -50C såsom beskrivits i exempel A och upparbetas på samma sätt. Man erhåller, efter kromatografering på silikagel och omkristallisering från diisopropyleter-metylenklorid, 1,5 g 17-hydroxi-3,3-(2',2'-dimetyl-1',3'-propylendioxi)-19-nor-5,15- resp. 5(10),15-pregnadien-20-on. Smp.: 241-249°C. 44,5 g 17-hydroxi-3,3-(2',2'-dimetyl-1',3'-propylendioxi)-19-nor- ~5,15~ resp. 5(10),15-pregnadien-20-on omsättes i 440 ml abs. tet- rahydrofuran med 45 g litium-tri-tert.-butoxialanat såsom beskrivits i exempel A och upparbetas på samma sätt. Man erhåller efter kroma- tografering på silikagel 37,6 g 17,205-dihydroxi-3,3-(2',2'-dimetyl- -1',3'-propylendioxi)-19-nor-5,15- resp. 5(10),15-pregnadien. 35,6 g 17,20¿-dihydroxi-3,3-(2',2'-dimetyl-1',3'~propylendioxi)-19- -nor-5,15- resp. 5(10),15-pregnadien upphettas i 475 ml abs. eter och 475 m] abs. etylenglykoldimetyleter med 57,3 ml metylenjodid uvh 71,2 g zinkkoppnr 0! iimmv undvr omrörning med åtorflöde.B) 3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -15a, 16a-methylene-5 (6) - or 5 (10) -estren-17-one. 5.0 g of 19-nor-4,16-pregnadiene-3,20-dione is heated in 250 ml of benzene with 4.0 g of 2,2-dimethyl-1,3-propanediol and 300 mg of p-toluenesulfonic acid for 2 hours. with water separator and backflow. The mixture is worked up as described in Example 1. After chromatography on silica gel, 4.9 g of 3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -19-nor--5 are obtained. , 16- resp. 5 (10), 16-pregnadien-20-one. UV: e239 = 9200. 5.0 g 3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -19-nor-5,16- resp. (10) A6-pregnadien-20-one is reacted with potassium tert-butylate solution, oxygen and trimethyl phosphite at -50 ° C as described in Example A and worked up in the same manner. After chromatography on silica gel and recrystallization from diisopropyl ether-methylene chloride, 1.5 g of 17-hydroxy-3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -19-nor-5, 15- resp. 5 (10), 15-pregnadien-20-one. Mp: 241-249 ° C. 44.5 g of 17-hydroxy-3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -19-nor- ~ 5,15 ~ resp. 5 (10), 15-pregnadien-20-one is reacted in 440 ml of abs. tetrahydrofuran with 45 g of lithium tri-tert-butoxyalanate as described in Example A and worked up in the same manner. After chromatography on silica gel, 37.6 g of 17,205-dihydroxy-3,3- (2 ', 2'-dimethyl--1', 3'-propylenedioxy) -19-nor-5,15- resp. 5 (10), 15-pregnadien. 35.6 g of 17,20β-dihydroxy-3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -19--nor-5,15- resp. 5 (10), 15-pregnadiene is heated in 475 ml abs. ether and 475 m] abs. ethylene glycol dimethyl ether with 57.3 ml of methylene iodide based on 71.2 g of zinc cup no. iimmv avoid stirring with return flow.
Blandningen upparbutas såsom beskrivits i exempel A. Man erhåller efter kromatografering på silikagel 17,7 g 17,20C-dihydroxi-3,3- -(2',2'-dimetyl-1',3'-propylendioxi)-15a,16a-mety1en-19-nor-5- resp. 5(10)-pregnen. 7713896-4 8 17 g 17,205-dihydroxi-3,3-(2',2'-dimetyl-1',3'-propylendioxi)-15a, 16u-metylen-19-nor-5- resp. 5(10)-pregnen omsättes i 1,35 ml metylen- klorid med 51 g pyridin-kromsyra-komplex 1 timme vid rumstemperatur och upparbetas såsom beskrivits i exempel A. Man erhåller efter kro- matografering på silikagel 7,4 g 3,3-(2',-2'-dimetyl-1',3'-propylen- dioxi)-15u,16a-metylen-5- resp. 5(10)-östren-17-on. Ett från hexan omkristalliserat prov smälter vid 173-177°C.The mixture is prepared as described in Example A. After chromatography on silica gel, 17.7 g of 17,20C-dihydroxy-3,3- - (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -15a, 16a are obtained. -methyl-19-nor-5- resp. 5 (10) -pregnen. 7713896-4 8 17 g 17,205-dihydroxy-3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -15a, 16u-methylene-19-nor-5- resp. The 5 (10) impregnates are reacted in 1.35 ml of methylene chloride with 51 g of pyridine-chromic acid complex for 1 hour at room temperature and worked up as described in Example A. After chromatography on silica gel, 7.4 g of 3.3 are obtained. - (2 ', - 2'-dimethyl-1', 3'-propylene dioxy) -15u, 16a-methylene-5- resp. 5 (10) -estren-17-one. A sample recrystallized from hexane melts at 173-177 ° C.
De fria oxo-föreningarna kan medelst kända förfaringssätt framstäl- las av ketalerna.The free oxo compounds can be prepared from the ketals by known methods.
Följande exempel belyser uppfinningen utan att begränsa densamma.The following examples illustrate the invention without limiting it.
Exempel 1 _ 900 mg magnesiumspân omsättes i 13 ml. abs. tetrahydrofuran med 2,93 ml etylbromid till etylmagnesiumbromid. Denna lösning sättes dropp- vis vid iskylning till 26 ml abs. tetrahydrofuran, genom vilken ace- tylen ledes. Till denna etinylmagnesiumbromidlösning sättes en lös- ning av 900 mg naturlig 3,3-(2',-2'-dimetyl-1',3'-propylendioxi)- -18-metyl-15a,16a-metylen-5- resp. 5(10)-östren-17-on i 25 ml abs. tetrahydrofuran och blandningen omröres 3 timmar vid rumstemperatur.Example 1 - 900 mg of magnesium turnings are reacted in 13 ml. abs. tetrahydrofuran with 2.93 ml of ethyl bromide to ethyl magnesium bromide. This solution is added dropwise upon ice-cooling to 26 ml of abs. tetrahydrofuran, through which acetylene is passed. To this ethinylmagnesium bromide solution is added a solution of 900 mg of natural 3,3- (2 ', - 2'-dimethyl-1', 3'-propylenedioxy) - -18-methyl-15a, 16a-methylene-5- resp. 5 (10) -estren-17-one in 25 ml abs. tetrahydrofuran and the mixture is stirred for 3 hours at room temperature.
Till överskottet av grignardreaktionskomponent sättas därefter ammo- niumkloridlösning och vattenfasen extraheras med eter. Man erhåller efter torkning och indunstning 910 mg naturlig 3,3-(2,'-2'-dimety1- -1',3'-propylendioxi)-18-metyl-17a-etinyl-15a,16a-metylen-5- resp. s(1o)-östren-173-01.To the excess grignard reaction component is then added ammonium chloride solution and the aqueous phase is extracted with ether. After drying and evaporation, 910 mg of natural 3,3- (2 '' - 2'-dimethyl-1 ', 3'-propylenedioxy) -18-methyl-17a-ethinyl-15a, 16a-methylene-5 and . s (1o) -östren-173-01.
NMR: ppm 0,86, 0,91, 0,98, 1,05, 1,06, 2,62, 3,30-3,70, 5,46 (cDc13l1 _ - IR: cm 3390, 3280, 2090, 1105, 1065 (KBr) Exempel 2 _ 900 mg rå naturlig 3,3-(2',-2'-dimetyl-1', 3'-propylendioxi)'18-me- tyl-17u-etinyl-15a,16a-metylen-5- resp. 5(10)-östren-176-ol upphet- tas i 10 ml metanol med 1,08 g oxalsyra i 2,5 ml vatten 45 minuter med återflöde. Blandningen spädes därefter med eter, tvättas neutral med vatten, torkas och indunstas i vakuum till torrhet. Återstoden kromatograferas på kiselgel. Man erhåller, efter omkristallisering från diisopropyleter, 500 mg naturlig 178-hydroxi-18-metyl-17a-eti- nyl-15u,16a-metylen~4-östren-3-on. Smp.: 189,5-191°C.NMR: ppm 0.86, 0.91, 0.98, 1.05, 1.06, 2.62, 3.30-3.70, 5.46 (cDc13111 - IR: cm -1 3390, 3280, 2090 , 1105, 1065 (KBr) Example 2 - 900 mg crude natural 3,3- (2 ', - 2'-dimethyl-1', 3'-propylenedioxy) '18-methyl-17u-ethinyl-15a, 16a -methylene-5- and 5 (10) -oestren-176-ol are heated in 10 ml of methanol with 1.08 g of oxalic acid in 2.5 ml of water for 45 minutes at reflux, the mixture is then diluted with ether, washed neutral with water, dried and evaporated in vacuo to dryness The residue is chromatographed on silica gel to give, after recrystallization from diisopropyl ether, 500 mg of natural 178-hydroxy-18-methyl-17α-ethinyl-15H, 16α-methylene-4-estrenic acid. 3-one, mp: 189.5-191 ° C.
UV: 6240 = 17 200.' 7713896-4 Exempel 3 2,0 g magnesiumspån omsättes såsom beskrivits i exempel 1 till eti- nylmagnesiumbromid och därtill sättes 2,0 g 3,3-(2',2'-dimetyl- -1',3'-propylendioxi)-15d,16u-metylen-5- resp. 5(10)-östren-17-on i 20 ml abs. tetrahydrofuran och blandningen omröres 2; timme vid rumstemperatur. Man erhåller efter upparbetning 2,0 g 3,3-(2',2'- -dimetyl-1',3'-propylendioxi)-17a-etinyl-15a,16a-metylen-5- resp. 5(10)-östren-176-ol.UV: 6240 = 17 200. ' Example 3 2.0 g of magnesium turnings are reacted as described in Example 1 to ethinylmagnesium bromide and to this is added 2.0 g of 3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) - 15d, 16u-methylene-5- resp. 5 (10) -estren-17-one in 20 ml abs. tetrahydrofuran and the mixture is stirred 2; hour at room temperature. After work-up, 2.0 g of 3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -17α-ethinyl-15α, 16α-methylene-5- and 5 (10) -estren-176-ol.
NMR: ppm 0,86, 0,91, 0,98, 1,05, 1,14, 2,62, 3,30-3,70, 5,46«IK13) IR: cm_1 3360, 3280, 2100, 1105, 1060 (KBr) Exempel 4 TiIl2,5 g1å3,3-(2',2'-dimetyl-1',3'-propylendixoi)-17a-etinyl-15a, 16a-metylen-5- resp. 5(10)-östren-176-ol i 20 ml metanol sättes 2,0 g oxalsyra i 2,2 ml vatten och blandningen upphettas 2 timmar med återflöde. Blandningen upparbetas såsom beskrivits i exempel 2. Man erhåller, efter kromatografering på silikagel och omkristallisering från diisopropyleter-metylenklorid, 1,2 g 17ß~hydroxi~17a-etinyl- -15a,16u-metylen-4-östren-3-on. Smp.: 145-146°C.NMR: ppm 0.86, 0.91, 0.98, 1.05, 1.14, 2.62, 3.30-3.70, 5.46 (IK13) IR: cm -1 3360, 3280, 2100, 1105, 1060 (KBr) Example 4 Til2.5 g1a3,3- (2 ', 2'-dimethyl-1', 3'-propylendixol) -17a-ethinyl-15a, 16a-methylene-5- resp. 5 (10) -Estrene-176-ol in 20 ml of methanol is added 2.0 g of oxalic acid in 2.2 ml of water and the mixture is heated at reflux for 2 hours. The mixture is worked up as described in Example 2. After chromatography on silica gel and recrystallization from diisopropyl ether-methylene chloride, 1.2 g of 17β-hydroxy-17α-ethinyl-15α, 16H-methylene-4-estren-3-one are obtained. Mp: 145-146 ° C.
UV: 6239 = 17 700.UV: 6239 = 17,700.
Exempel 5 600 mg naturlig 173-hydroxi-18-metyl-17d-etinyl-15a,16a-mety1en-4- -östren-3-on upphettas i 2 ml acetanhydrid och 2 ml pyridin 10 tim- mar i en kvävgasström med âterflöde. Blandningen hälles därefter i isvatten. Den utskilda fällningen avfiltreras, tvättas med vatten och torkas. För att spalta det därvid bildade 3-enolacetatet tages produkten upp i 30 ml metanol och upphettas med 0,3 ml konc. klor- vätesyra 15 minuter med återflöde. Fällningen, efter utfällning i isvatten, avfiltreras, tvättas med vatten och torkas. Man erhåller, efter kromatografering på silikagel, 510 mg naturlig 17B-acetoxi-18- -mety1~17a-etinyl-15a,16a-metylen-4-östren-3-on. Smp.: 167,5-169,5°C (omkristalliserad från diisopropyleter). UV: 2240 = 17 600.Example 5 600 mg of natural 173-hydroxy-18-methyl-17d-ethinyl-15a, 16a-methylene-4-estren-3-one are heated in 2 ml of acetane anhydride and 2 ml of pyridine for 10 hours in a stream of nitrogen with reflux. The mixture is then poured into ice water. The separated precipitate is filtered off, washed with water and dried. To cleave the 3-enol acetate thus formed, the product is taken up in 30 ml of methanol and heated with 0.3 ml of conc. hydrochloric acid 15 minutes with reflux. The precipitate, after precipitation in ice water, is filtered off, washed with water and dried. After chromatography on silica gel, 510 mg of natural 17β-acetoxy-18-methyl-17α-ethinyl-15α, 16α-methylene-4-estren-3-one are obtained. Mp: 167.5-169.5 ° C (recrystallized from diisopropyl ether). UV: 2240 = 17,600.
Exempel 6 500 mg naturlig 17S-hydroxi-18-metyl-17d-etinyl-15a,16d~metylen-4- -östren-3-on upphettas i 2 ml smörsyraanhydrid och 2 ml pyridin 10 timmar i hvävgasström vid 160°C. Blandningen upparbetas därefter såsom beskrivits i exempel 5 och 3-enolestern spaltas på samma sätt.Example 6 500 mg of natural 17S-hydroxy-18-methyl-17d-ethinyl-15a, 16d-methylene-4-estren-3-one are heated in 2 ml of butyric anhydride and 2 ml of pyridine for 10 hours in a stream of nitrogen at 160 ° C. The mixture is then worked up as described in Example 5 and the 3-enol ester is cleaved in the same manner.
Man erhåller, efter kromatografering på silikagel, 450 mg natürlig 176-butyryloxi-18-metyl-1Tu-etinyl-15a,16u-metylen-4-östren-3-on. vv; C240 = 16 eoo. 7713896-4 10 Smp.: 118-122°C (omkristalliserad från pentan).After chromatography on silica gel, 450 mg of natural 176-butyryloxy-18-methyl-1H-ethinyl-15α, 16H-methylene-4-estren-3-one are obtained. vv; C240 = 16 eoo. M.p .: 118-122 ° C (recrystallized from pentane).
Exempel 7 500 mg naturlig 17ß-hydroxi-18-metyl-17a-etinyl-15a,16a-metylen-4- -östren-3-on upphettas i 2 ml önantsyraanhydrid och 2 ml pyridin 17 timmar i kvävgasström vid 170°C. Blandningen upparbetas därefter såsom beskrivits i exempel 5 och 3-enolestern spaltas på samma sätt. överskottet av önantsyra avlägsnas genom vattenângdestillation. Den efter extraktion med eter erhållna produkten kromatograferas på sili- kagel, varvid man erhåller 380 mg naturlig 17ß4heptanyloxi-18-metyl- -17a-etinyl-15a,1Ga-metylen-4-östren-3-on som olja. UV: s240 = 17000 Exempel 8 400 mg 173-hydroxi-17a-etinyl-15a,16a-metylen-4-östren-3-on omsättes i 2 ml acetanhydrid och 2 ml pyridin såsom beskrivits i exempel 5 och upparbetas på samma sätt. Man erhåller, efter kromatografering på silikagel, 390 mg 176-acetoxi-17a-etinyl-15a,16a-metylen-4-östren- -3-on. vv; 2240 = 17 100. ' Exempel 9 150 mg 176-hydroxi~17u-etinyl-15u,1Gu-metylen-4-östren-3-on omsät- tes i 1 ml smörsyraanhydrid och 1 ml pyridin såsom beskrivits i exem- pel 5 och upparbetas på samma sätt. Man erhåller, efter kromatogra- fering på silikagel, 130 mg 17ß-butyryloxi-17a¥etinyl-15a,16a-metyler -4-östren-3-on. UV: s239 = 17 400.Example 7 500 mg of natural 17β-hydroxy-18-methyl-17α-ethinyl-15α, 16α-methylene-4-estren-3-one are heated in 2 ml of enanoic anhydride and 2 ml of pyridine for 17 hours in a stream of nitrogen at 170 ° C. The mixture is then worked up as described in Example 5 and the 3-enol ester is cleaved in the same manner. the excess island acid is removed by water vapor distillation. The product obtained after extraction with ether is chromatographed on silica gel to give 380 mg of natural 17β-heptanyloxy-18-methyl-17α-ethinyl-15α, 1Ga-methylene-4-estren-3-one as an oil. UV: s240 = 17000 Example 8 400 mg of 173-hydroxy-17α-ethinyl-15α, 16α-methylene-4-estren-3-one are reacted in 2 ml of acetane anhydride and 2 ml of pyridine as described in Example 5 and worked up in the same manner. After chromatography on silica gel, 390 mg of 176-acetoxy-17α-ethinyl-15α, 16α-methylene-4-estren--3-one are obtained. vv; 2240 = 17,100. Example 9 150 mg of 176-hydroxy-17H-ethinyl-15u, 1Gu-methylene-4-estren-3-one are reacted in 1 ml of butyric anhydride and 1 ml of pyridine as described in Example 5 and processed in the same way. After chromatography on silica gel, 130 mg of 17β-butyryloxy-17α-ethinyl-15α, 16α-methyls-4-estren-3-one are obtained. UV: s239 = 17,400.
Exempel 10 h 7 150 mg 176-hydroxi-17a-etinyl-15a,16a~metylen-4-östren-3-on omsät- tes i 1 ml önantsyraanhydrid och 1 ml pyridin såsom beskrivits i exer pel 5 och upparbetas pâ samma sätt. Man erhåller, efter kromatografei ring på silikagel, 140 mg 175-heptanoyloxi-17a-etinyl-15u,16u-metyle1 -4-östren-3-on som olja, UV: s239 = 17 200. 0 Exempel 11 Till 250 mg naturlig 17ß-hydroxi-18-metyl-17a-etinyl-15d,16a-mety- len-4-östren-3-on i 20 ml abs. tetrahydrofuran sättes 800 mg liti- um-tri-tert.-butoxialanat och blandningen omröres 1 timme vid rums- temperatur. ßlundníngvn rörus därefter in i isvnttcn, surgöres med utspädd svavelsyra, extraheras med metylenklorid och metylenklorid- fasen tvättas neutral. 240 mg råprodukt erhålles efter torkning och indunstning. Män erhåller, efter omkristallisering från diisopropyl- eter, 140 mg naturlig 38,178-dihydroxi-18-metyl-17u-etinyl-15u,16a- 7713896-4 11 -metylen-4~östren. Smp.: 183-187OC. gkempel 12 Till 300 mg 178-hydroxi-17u-etinyl-15a,16a-metylen-4-östren-3-on i 25 ml abs. tetrahydrofuran sättes 950 mg 1itiumtri-tert.~butoxi- -alanat och blandningen omröres 1 timme vid rumstemperatur. Blandnin- gen upparbetas såsom beskrivits i exempel 11. Man erhåller, efter kromatografering på silikagel, 250 mg 3ß,17B-dihydroxi-17a-etinyl- -15a,16a-metylen-4-östren. UV: 5209 = 3800.Example 10 h 7 150 mg of 176-hydroxy-17α-ethinyl-15α, 16α-methylene-4-estren-3-one are reacted in 1 ml of enanoic anhydride and 1 ml of pyridine as described in Example 5 and worked up in the same manner. After chromatography on silica gel, 140 mg of 175-heptanoyloxy-17α-ethinyl-15u, 16u-methyl-4-estren-3-one are obtained as oil, UV: s239 = 17,200. Example 11 To 250 mg of natural 17β -hydroxy-18-methyl-17α-ethinyl-15d, 16α-methylene-4-estren-3-one in 20 ml abs. tetrahydrofuran is added 800 mg of lithium tri-tert-butoxyalanate and the mixture is stirred for 1 hour at room temperature. The slurry is then stirred into the ice bath, acidified with dilute sulfuric acid, extracted with methylene chloride and the methylene chloride phase is washed neutral. 240 mg of crude product are obtained after drying and evaporation. Men receive, after recrystallization from diisopropyl ether, 140 mg of natural 38,178-dihydroxy-18-methyl-17u-ethinyl-15u, 16a-methylene-4-esters. M.p .: 183-187OC. Example 12 To 300 mg of 178-hydroxy-17H-ethinyl-15α, 16α-methylene-4-estren-3-one in 25 ml of abs. tetrahydrofuran is added 950 mg of lithium tri-tert-butoxy-alanate and the mixture is stirred for 1 hour at room temperature. The mixture is worked up as described in Example 11. After chromatography on silica gel, 250 mg of 3β, 17β-dihydroxy-17α-ethinyl-15α, 16α-methylene-4-esters are obtained. UV: 5209 = 3800.
Exempel 13 _ 300 mg naturlig 3ß,176-dihydroxi-18-metyl-17a-etinyl-15u,16a-mety- len-4-östren får stå i 1 ml pyridin med 0,5 ml acetanhydrid 18 tim- mar vid rumstemperatur. Blandningen röres in i isvatten. Den utskil- da fällningen avfiltreras, tvättas med vatten och torkas. Man erhål- ler 320 mg naturlig 176-hydroxi-35-acetoxi-18-metyl-17u-etinyl-15a, 16u-metylen-4-östren. Smp.: 117-118,5°C.Example 13 - 300 mg of natural 3β, 176-dihydroxy-18-methyl-17α-ethinyl-15β, 16α-methylene-4-esters are allowed to stand in 1 ml of pyridine with 0.5 ml of acetane anhydride for 18 hours at room temperature. The mixture is stirred into ice water. The separated precipitate is filtered off, washed with water and dried. 320 mg of natural 176-hydroxy-35-acetoxy-18-methyl-17u-ethinyl-15a, 16u-methylene-4-esters are obtained. Mp: 117-118.5 ° C.
Exempel_lí 250 mg 3ß,1VB-dihydroxi-17a-etinyl-15a,16u-metylen-4-östren omsättes i 1 ml pyridin med 0,5 ml acetanhydrid såsom beskrivits i exempel 13 och upparbetas på samma sätt. Man erhåller 260 mg 17B-hydroxi-3B- acetoxi-17a-etinyl-15a,16a~metylen-4-östren. UV: EZO9 = 3300. ¶Éë¶ÉÉ-lÉ . 100 mg naturlig 38,178-dihydroxi-18-metyl-17u-etinyl-15a,16a-mety- len-4-östren upphettas i 1 ml pyridin och 1 ml ättiksyraanhydrid 10 timmar i kvävgasström med återflöde. Blandningen röres därefter in i isvatten. Den utskilda fällningen avfiltreras, tvättas med vatten och torkas. Man erhåller efter kromatografering på silikagel, 60 mg na- turlig 38,17ß-diacetoxi-1Emetyl-17u-etinyl-15a,16a-metylen-4-östren.Example 1 - 250 mg of 3β, 11β-dihydroxy-17α-ethinyl-15α, 16β-methylene-4-esters are reacted in 1 ml of pyridine with 0.5 ml of acetane anhydride as described in Example 13 and worked up in the same manner. 260 mg of 17β-hydroxy-3β-acetoxy-17α-ethinyl-15α, 16α-methylene-4-esters are obtained. UV: EZO9 = 3300. ¶Éë¶ÉÉ-lÉ. 100 mg of natural 38,178-dihydroxy-18-methyl-17u-ethinyl-15a, 16a-methylene-4-esters are heated in 1 ml of pyridine and 1 ml of acetic anhydride for 10 hours in a stream of refluxed nitrogen. The mixture is then stirred into ice water. The separated precipitate is filtered off, washed with water and dried. After chromatography on silica gel, 60 mg of natural 38,17β-diacetoxy-1Emethyl-17H-ethinyl-15α, 16α-methylene-4-esters are obtained.
UV: 6209 = 3600.UV: 6209 = 3600.
Exempel 16 125 mg 38,17ß-dihydroxi-17u-etinyl-15a,16u-metylen-4-östren upphet- tas i 1 ml pyridin och 1 ml ättiksyraanhydrid 10 timmar i kvävgas- ström med återflöde. Blandningen upparbetas såsom beskrivits i exem- pel 15. Man erhåller, efter kromatografering på silikagel, 70 mg 3ß,17ß-diacetoxi-17a-etinyl-15u,16a-metylen-4-östren. UV: ezog ~ 3350. åëflfålll Till 200 mg naturlig 178-acetoxi-18-metyl-17u-etinyl-15u,16a-metylen- 7713896-4 12 -4-östren-3-on i 20 ml abs. tetrahydrofuran sättes 670 mg litium- tri-tert.-butoxialanat och blandningen omröres 1 timme vid rumstem- peratur. Blandningen upparbetas såsom beskrivits i exempel 11. Man erhåller, efter kromatografering på silikagel, 160 mg naturlig 36- -hydroxi-17ß-acetoxi-18-metyl-17u-etinyl-15d,16a-metylen-4-östren.Example 16 125 mg of 38,17ß-dihydroxy-17u-ethinyl-15a, 16u-methylene-4-esters are heated in 1 ml of pyridine and 1 ml of acetic anhydride for 10 hours in a stream of nitrogen at reflux. The mixture is worked up as described in Example 15. After chromatography on silica gel, 70 mg of 3β, 17β-diacetoxy-17α-ethinyl-15β, 16α-methylene-4-esters are obtained. UV: ezog ~ 3350. åë fl case To 200 mg natural 178-acetoxy-18-methyl-17u-ethinyl-15u, 16a-methylene-7713896-4 12 -4-estren-3-one in 20 ml abs. tetrahydrofuran is added 670 mg of lithium tri-tert-butoxyalanate and the mixture is stirred for 1 hour at room temperature. The mixture is worked up as described in Example 11. After chromatography on silica gel, 160 mg of natural 36--hydroxy-17β-acetoxy-18-methyl-17H-ethinyl-15d, 16α-methylene-4-esters are obtained.
UV: s = 3550. 209 Exemgel 18 -_ *Till 150 mg 176-acetoxi-17u-etinyl-15u,16u-metylen-4-östren-3-on i 15 ml abs. tetrahydrofuran sättes 500 mg litiumtri-tert.-butoxi-ala- nat och blandningen omröres 1 timme vid rumstemperatur. Blandningen upparbetas såsom beskrivits i exempel 11. Man erhåller, efter kroma- tografering på silikagel, 105 mg 38-hydroxi-178-acetoxi-17a-etinyl- -15u,16a-metylen-4-östren. UV: 6209 = 3600.UV: s = 3550. 209 Exemgel 18-* To 150 mg 176-acetoxy-17u-ethinyl-15u, 16u-methylene-4-estren-3-one in 15 ml abs. tetrahydrofuran is added 500 mg of lithium tri-tert-butoxy-alanate and the mixture is stirred for 1 hour at room temperature. The mixture is worked up as described in Example 11. After chromatography on silica gel, 105 mg of 38-hydroxy-178-acetoxy-17α-ethinyl-15H, 16α-methylene-4-esters are obtained. UV: 6209 = 3600.
Exemgel 19 Till en metyllitiumlösning, framställd av 185 mg litium och 0,83 ml metyljodid i 15 ml abs. eter, sättes 670 mg trans-dikloretylen i 3 ml abs. eter och blandningen omröres 1š timme vid rumstemperatur.Example gel 19 To a methyl lithium solution, prepared from 185 mg of lithium and 0.83 ml of methyl iodide in 15 ml of abs. ether, 670 mg of trans-dichloroethylene is added to 3 ml of abs. ether and the mixture is stirred for 1 hour at room temperature.
Till denna lösningav litiumkloracetylid sättes droppvis 500 mg na- turlig 3,3-(2',2'-dimetyl-1',3'-propylendioxi)-18-metyl-15a,16a-mety- len-5- resp. 5(10)-östren-17-on löst i 20 ml abs. toluen inom 15 mi- nuter och därefter upphettas blandningen 2% timme med âterflöde. över- skottet av reaktionskomponent sönderdelas därefter under kylning med en ammoniumkloridlösning. Blandningen spädes med eter och tvättas neutral med vatten.Man erhåller, efter indunstning 520 mg rå natur- lig 3,3-(2',2'-dimetyl-1',3'-propylendioxi)-18-metyl-17u-kloretinyl- -15a,16a-metylen-5- resp. 5(10)-östren-176-ol.To this solution of lithium chloroacetylide is added dropwise 500 mg of natural 3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -18-methyl-15a, 16a-methylene-5- and 5 (10) -estren-17-one dissolved in 20 ml abs. toluene within 15 minutes and then the mixture is heated for 2% hour with reflux. the excess reactant is then decomposed while cooling with an ammonium chloride solution. The mixture is diluted with ether and washed neutral with water. After evaporation, 520 mg of crude natural 3,3- (2 ', 2'-dimethyl-1', 3'-propylenedioxy) -18-methyl-17u-chloroethinyl are obtained. - -15a, 16a-methylene-5- resp. 5 (10) -estren-176-ol.
Exempel 20 520 mg rå naturlig 3,3-(2',2'-dimetyl-1',-3'-propylendioxi)-18-metyl- -17a-kloretinyl-15u,16u-metylenw5- resp. 5(10)-östren-17ß-ol.upphet- tas i 20 ml metanol med 500 mg oxalsyra i 2,5 ml vatten 45 minuter med återflöde. Blandningen upparbetas såsom beskrivits i exempel 6.Example 20 520 mg of crude natural 3,3- (2 ', 2'-dimethyl-1', - 3'-propylenedioxy) -18-methyl--17α-chloroethinyl-15u, 16u-methylenew5- resp. 5 (10) -Easter-17β-ol. Is heated in 20 ml of methanol with 500 mg of oxalic acid in 2.5 ml of water for 45 minutes at reflux. The mixture is worked up as described in Example 6.
Man erhåller, efter kromatografering på silikagel, 280 mg naturlig 176-hydroxi-18-metyl-17a-kloretinyl-15a,1&r¶ætylen-4-östren-3-on.After chromatography on silica gel, 280 mg of natural 176-hydroxy-18-methyl-17α-chloroethinyl-15α, 1H-ethylene-4-estren-3-one are obtained.
UV: C240 = 17 200.UV: C240 = 17 200.
Exemgel 21 150 mg naturlig 36,178-dihydroxi-18-metyl-17a-etinyl-1Sa,16a~mety- len-4-östren får stå vid rumstemperatur 15 timmar med 1 ml önant- syraanhydrid och 0,5 ml pyridin. Man erhåller, efter upparbetning 7713896-4' 13 såsom beskrivits i exempel 13, 100 mg naturlig 17ß-hydroxi-3B-hep- tanoyloxi-18-metyl-17a-etinyl-15a,16u~metylen-4-östren som olja.Example 21 21 mg of natural 36,178-dihydroxy-18-methyl-17α-ethinyl-1Sa, 16α-methylene-4-esters are allowed to stand at room temperature for 15 hours with 1 ml of enanthic anhydride and 0.5 ml of pyridine. After work-up 7713896-4 '13 as described in Example 13, 100 mg of natural 17β-hydroxy-3β-heptanoyloxy-18-methyl-17α-ethinyl-15α, 16α-methylene-4-esters are obtained as an oil.
UV:E210 = 3100.UV: E210 = 3100.
Exempel 22 250 mg naturlig 36-hydroxi-176-acetoxi-18-metyl-17a-etinyl-15u,16d- -metylen-4-östren får stå vid rumstemperatur 18 timmar med 2,5 ml kollidin och 1,5 ml kaprylsyraanhydrid. Man erhåller, efter upparbet- ning såsom beskrivits i exempel 13, 180 mg 17ß-acetoxi-3ß-oktanoyl- oxi-18-metyl-17u-etinyl-15a,16a-metylen-4-östren som olja.Example 22 250 mg of natural 36-hydroxy-176-acetoxy-18-methyl-17α-ethinyl-15u, 16d-methylene-4-esters are allowed to stand at room temperature for 18 hours with 2.5 ml of collidine and 1.5 ml of caprylic anhydride. After work-up as described in Example 13, 180 mg of 17β-acetoxy-3β-octanoyloxy-18-methyl-17β-ethinyl-15α, 16α-methylene-4-esters are obtained as oil.
UV:6209 = 3200..UV: 6209 = 3200 ..
Jämförelseexempel Föreningarna enligt uppfinningen undersöktes beträffande gestagen verkan i jämförelse med motsvarande 156,166-metylen-föreningar, vil- ka är förut kända genom danska patentskriften 119 429.Comparative examples The compounds according to the invention were tested for progestogenic activity in comparison with the corresponding 156,166-methylene compounds, which are previously known from Danish patent specification 119 429.
Undersökningsresultaten har sammanställts i nedanstående tabell. En- ligt det ovan beskrivna Clauberg-testet bestämdes, efter subkutan app- licering av de verksamma substanserna, den sekretoriska omvandlingen av Endometrium på kastrerade kaniner. Bestämningen skedde medelst Mc Phail-skalan (bedömningsgrader 1-4, varvid 1 = ingen verkan och 4 = fullständig omvandling). 7713896-4 14 Clauberg-Teet s.k.The survey results have been compiled in the table below. According to the Clauberg test described above, after subcutaneous application of the active substances, the secretory conversion of Endometrium to castrated rabbits was determined. The determination was made using the Mc Phail scale (grades 1-4, with 1 = no effect and 4 = complete conversion). 7713896-4 14 Clauberg-Teet s.k.
Förening 'Dos (mg) neïnail 175-hydroxí-18~metyl- 0,5 5,2 -17u-etínyl-15a,16a-metylen- '0,1 5,1 -4-östren-3-on 0,0§ 2,0 0,01 1,5 «7ß~acet0xi-13-mety1- 0,1 5,2 -17a-etinyl-15a,16a-metylen ' 0,05 5,0 -4-östren-3-on 0,01 1,0 17B-hydroxi-18-metyl-' 0,5 2,9 -17u-etinyl-155,16fi-mety1en- 0,1 1,8 -4-östren-š-on 0,03 1,0 (danska patentet 119 429) 17E4nydroxi-17a-etínyl- 0,1 2,5 -151,16:-metylen-4-östren 0,03 1,2 -5-on 0,01 1,1 17§-hy§roxí-1?a-etínyl- 1,0 1,9 -153,163-metylen-4-östren-E-on 0,1 1,0 (danska patent 115 585) Av tabellen framgår att 1Ba,16u-metylenföreníngarna enligt uppfinningen är ca 10 ggr verksammare än de kända 15ß,16fi-me- tylenföreníngarna.Compound 'Dose (mg) of nail 175-hydroxy-18-methyl-0,5,2,2 -17u-ethinyl-15α, 16α-methylene-0,1,1,1,1-4-estren-3-one 0.0 § 2.0 0.01 1.5 «7ß-acetoxy-13-methyl-0.1 5.2-17α-ethinyl-15a, 16a-methylene '0.05 5.0 -4-estren-3-one 0.01 1.0 17B-hydroxy-18-methyl- '0.5 2.9 -17u-ethinyl-155.16 fi-methylene-0.1 1,8 -4-estren-s-one 0.03 1 (Danish patent 119,429) 17E4nydroxy-17α-ethinyl-0.1 2,5 -151.16: -methylene-4-esters 0.03 1,2 -5-one 0.01 1.1 17§- hydroxy-1α-ethinyl-1,0 1,9 -153,163-methylene-4-estren-E-one 0,1 1,0 (Danish patent 115 585) The table shows that the 1Ba, 16u-methylene compounds according to the invention is about 10 times more effective than the known 15β, 16β-methylene compounds.
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2207421A DE2207421C3 (en) | 1972-02-11 | 1972-02-11 | 15?, 16? -Methylene-4-oestrene-17? -ols or acylates, processes for their production and medicaments containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7713896L SE7713896L (en) | 1977-12-07 |
| SE426834B true SE426834B (en) | 1983-02-14 |
Family
ID=5836211
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7301935A SE403781B (en) | 1972-02-11 | 1973-02-12 | METHOD OF PRODUCING 15 ALFA, 16 ALFA-METHYLENE-4-OSTRENE-17 BETA OLES |
| SE7514513A SE409329B (en) | 1972-02-11 | 1975-12-22 | 15 ALFA, 16 ALFA-METHYLENE-4-OSTRENE-17 BETA OLES FOR USE AS A CONTRACTIVE AGENT |
| SE7713896A SE426834B (en) | 1972-02-11 | 1977-12-07 | SET TO MAKE 15ALFA, 16ALFA METHYLENE-4-OSTREN-17BETA OILS |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7301935A SE403781B (en) | 1972-02-11 | 1973-02-12 | METHOD OF PRODUCING 15 ALFA, 16 ALFA-METHYLENE-4-OSTRENE-17 BETA OLES |
| SE7514513A SE409329B (en) | 1972-02-11 | 1975-12-22 | 15 ALFA, 16 ALFA-METHYLENE-4-OSTRENE-17 BETA OLES FOR USE AS A CONTRACTIVE AGENT |
Country Status (29)
| Country | Link |
|---|---|
| JP (1) | JPS5829317B2 (en) |
| KR (1) | KR780000156B1 (en) |
| AT (1) | AT327413B (en) |
| AU (1) | AU467306B2 (en) |
| BE (1) | BE795241A (en) |
| CA (1) | CA997753A (en) |
| CH (2) | CH590883A5 (en) |
| CS (1) | CS193019B2 (en) |
| DD (1) | DD102379A5 (en) |
| DE (1) | DE2207421C3 (en) |
| DK (1) | DK131037B (en) |
| EG (1) | EG10914A (en) |
| ES (1) | ES410933A1 (en) |
| FI (1) | FI52225C (en) |
| FR (1) | FR2181719B1 (en) |
| GB (1) | GB1425636A (en) |
| GR (1) | GR63160B (en) |
| HU (1) | HU165253B (en) |
| IE (1) | IE37266B1 (en) |
| IL (1) | IL41506A (en) |
| NL (1) | NL177217C (en) |
| NO (2) | NO140304C (en) |
| PH (1) | PH9370A (en) |
| PL (1) | PL81084B1 (en) |
| RO (1) | RO73527A (en) |
| SE (3) | SE403781B (en) |
| SU (1) | SU513628A3 (en) |
| YU (1) | YU35035B (en) |
| ZA (1) | ZA73944B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007027636A1 (en) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17β-Cyano-18α-homo-19-nor-androst-4-ene derivative, its use and the derivative-containing drug |
| DE102007027637A1 (en) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17β-cyano-19-nor-androst-4-ene derivative, its use and the derivative-containing drug |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT274653B (en) * | 1966-11-10 | 1969-09-25 | Alexander Schoeller & Co Kg | Stackable, rectangular, closed plastic transport container for fine-grained bulk goods and liquids |
-
0
- BE BE795241D patent/BE795241A/en not_active IP Right Cessation
-
1972
- 1972-02-11 DE DE2207421A patent/DE2207421C3/en not_active Expired
- 1972-12-29 PL PL1972159970A patent/PL81084B1/pl unknown
-
1973
- 1973-01-11 DD DD168198A patent/DD102379A5/xx unknown
- 1973-01-16 DK DK24273AA patent/DK131037B/en not_active IP Right Cessation
- 1973-01-23 FI FI730169A patent/FI52225C/en active
- 1973-01-24 ES ES410933A patent/ES410933A1/en not_active Expired
- 1973-01-31 CS CS73748A patent/CS193019B2/en unknown
- 1973-01-31 YU YU243/73A patent/YU35035B/en unknown
- 1973-02-06 IE IE190/73A patent/IE37266B1/en unknown
- 1973-02-06 CA CA163,029A patent/CA997753A/en not_active Expired
- 1973-02-07 EG EG49/73A patent/EG10914A/en active
- 1973-02-08 AT AT112473A patent/AT327413B/en not_active IP Right Cessation
- 1973-02-09 PH PH14330*UA patent/PH9370A/en unknown
- 1973-02-09 NO NO528/73A patent/NO140304C/en unknown
- 1973-02-09 FR FR7304678A patent/FR2181719B1/fr not_active Expired
- 1973-02-09 SU SU1891803A patent/SU513628A3/en active
- 1973-02-09 CH CH186373A patent/CH590883A5/xx not_active IP Right Cessation
- 1973-02-09 ZA ZA730944A patent/ZA73944B/en unknown
- 1973-02-09 GR GR1318A patent/GR63160B/en unknown
- 1973-02-09 CH CH535776A patent/CH593995A5/xx not_active IP Right Cessation
- 1973-02-09 IL IL41506A patent/IL41506A/en unknown
- 1973-02-10 KR KR7300246A patent/KR780000156B1/en not_active Expired
- 1973-02-10 RO RO7373805A patent/RO73527A/en unknown
- 1973-02-10 HU HUSE1666A patent/HU165253B/hu unknown
- 1973-02-12 SE SE7301935A patent/SE403781B/en unknown
- 1973-02-12 NL NLAANVRAGE7301974,A patent/NL177217C/en not_active IP Right Cessation
- 1973-02-12 JP JP48017357A patent/JPS5829317B2/en not_active Expired
- 1973-02-12 AU AU52076/73A patent/AU467306B2/en not_active Expired
- 1973-02-12 GB GB682173A patent/GB1425636A/en not_active Expired
-
1975
- 1975-12-22 SE SE7514513A patent/SE409329B/en not_active IP Right Cessation
-
1977
- 1977-12-07 SE SE7713896A patent/SE426834B/en not_active IP Right Cessation
-
1978
- 1978-08-14 NO NO782754A patent/NO143065C/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2669767C (en) | Progesterone receptor antagonists | |
| EP0349481B1 (en) | 13-Alkyl-11-beta-phenyl gonanes | |
| US4389345A (en) | 3-Oxoestra-17-acetonitrile and unsaturated analogs | |
| TW518339B (en) | 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives | |
| JP2717792B2 (en) | Novel 7-substituted 19-nor steroids, their preparation, use as medicaments and pharmaceutical compositions containing them | |
| DK143604B (en) | 18-METHYL-4,15 OESTRADIENTS FOR USE IN PREGNANCY PREVENTION | |
| EP0189951B1 (en) | New process for the preparation of certain steroids, especially intermediates for the preparation of proligestone and related compounds, and new intermediates formed in this process | |
| JPH0649717B2 (en) | Novel steroids substituted at the 10-position with a group containing a double bond or a triple bond, their production method and drug | |
| SE445225B (en) | SET TO MAKE STEROID COMPOUNDS | |
| EP0411736B1 (en) | 11-Beta substituted 16-alpha, 17-alpha-methylene-estra-4,9-dien-3-one | |
| SE426834B (en) | SET TO MAKE 15ALFA, 16ALFA METHYLENE-4-OSTREN-17BETA OILS | |
| JP2021183627A (en) | Methods for the production of 11-methylene steroids and novel intermediates | |
| US4016269A (en) | 17α-HYDROXY-1,3,5(10),15-ESTRATETRAENES AND PROCESS FOR THEIR PRODUCTION | |
| CS203912B2 (en) | Process for preparing derivatives of estradiene | |
| HU197925B (en) | Process for producing 11 beta-(aminophenyl)-steroids and pharmaceutical compositions comprising same | |
| Klimstra et al. | Anabolic Agents. A-Ring Conjugated Enone Androstane Derivatives1a | |
| US5866559A (en) | 17α-cyanomethylestra-4,9-dien derivatives and pharmaceutical compositions containing same | |
| HU177452B (en) | Process for preparing new d-homo-steroids | |
| JPS6050199B2 (en) | Steroid spirooxazolidine compounds | |
| US4022892A (en) | 17β-Ethynyl-3,17α-estradiol and derivatives thereof | |
| CA2427632C (en) | Process for the production of 4-(17.alpha.-substituted-3-oxoestra-4,9-dien-11.beta.-yl)benzaldehyde-(1e or 1z)-oximes | |
| US3983112A (en) | 17β-Ethynyl-3,17α-estradiol and derivatives thereof | |
| JPS6321680B2 (en) | ||
| US3398140A (en) | Steroido [17. 16-c] pyrozoles and preparation thereof | |
| US3248392A (en) | Steroid lactones and process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 7713896-4 Effective date: 19890425 Format of ref document f/p: F |